“Risk of urinary adverse effects of bevacizumab therapy in patients with ovarian cancer: a systematic review and meta-analysis”, Arch Ital Urol Androl, vol. 97, no. 4, Dec. 2025, doi: 10.4081/aiua.2025.14659.